Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT01590758 Completed - Clinical trials for Diabetic Foot Infection

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

OneStep-1
Start date: June 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care, as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.

NCT ID: NCT01587131 Completed - Clinical trials for Respiratory Tract Infections

DNA-based Influenza Vaccine in the Elderly

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether FVH1, a DNA-based influenza vaccine, will be safe and generally well tolerated in healthy elderly adult volunteers and will result in greater immunogenicity when used to prime the immune response to a dose of a trivalent inactivated seasonal vaccine.

NCT ID: NCT01582711 Completed - Clinical trials for Latent Tuberculosis Infection

Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

iAdhere
Start date: September 2012
Phase: Phase 3
Study type: Interventional

The study is an open label, multicenter, randomized (three arms: DOT (standard control), SAT, SAT with SMS reminders) controlled clinical trial. The trial is conducted in patients diagnosed with latent tuberculosis infection (LTBI) who are recommended for treatment. The primary objective is to evaluate adherence to a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) given by directly observed therapy (DOT) compared to self-administered therapy (SAT). The secondary objectives: - To compare the treatment completion rates between participants randomized to SAT without reminders versus SAT with weekly SMS reminders - To evaluate the timing of doses and patterns of adherence to once weekly RPT/INH among participants who complete treatment and those who discontinue therapy prior to completion. - To determine the availability and acceptability of using SMS reminders among all patients consenting to participate in the study. - To determine the toxicity and tolerability by comparing the rates of any drug-related grade 3 or 4 adverse events or death between the DOT arm and the SAT arms (both combined and individually) - To compare the frequency, timing, and causes for failure to complete treatment between the DOT arm and the SAT arms - To collect patient-specific cost data related to the 3 treatment arms - To describe the pattern of antituberculosis drug resistance among Mycobacterium tuberculosis strains cultured from participants who develop active TB.

NCT ID: NCT01580137 Active, not recruiting - Clinical trials for Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis

Acute Upper Respiratory Tract Infection - When is Bacteria Involved?

Start date: February 2012
Phase: N/A
Study type: Observational

The purpose of this study is to find out if we can predict the progress of acute upper respiratory tract infection to acute bacterial rhinosinusitis in Finnish conscripts by symptoms, clinical, endoscopic or radiological findings, middle meatal swab samples or nitric oxide measurement.

NCT ID: NCT01577862 Completed - Clinical trials for Pneumonia, Ventilator-Associated

Colistin and Rifampicin for MDR-Acinetobacter

CoRAb
Start date: November 2008
Phase: Phase 3
Study type: Interventional

Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients. It can acquire resistance to all classes of antibiotics (multidrug resistance, MDR) except an 'old' drug, colistin, which may be the only therapeutic option. However, colistin is not registered for this indication. The addition of rifampicin to colistin has been shown to be synergistic in vitro, and may be promising in vivo, but this combination has not been studied in comparison with colistin alone. The purpose of this randomised, open-label, multicentre clinical trial is to assess whether the association of colistin and rifampicin reduces significantly the mortality of patients with severe MDR A. baumannii infections compared with colistin alone. The trial will enroll 210 patients from intensive care units (ICU) of five tertiary care hospitals where MDR A. baumannii infection is endemic with epidemic phases. Patients will be randomly allocated to either colistin alone (control arm) or colistin plus rifampicin (experimental arm). Primary end point is overall mortality, defined as death occurring within 30 days from randomisation. Secondary end points will be disease-specific death, microbiological eradication, hospitalization length, emergence of resistance to colistin during treatment.

NCT ID: NCT01576003 Completed - Nutrition Clinical Trials

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the effects (good and bad) of supplementation with Glutamine to that of a placebo (L-alanine), on your child and their Short Bowel Syndrome. Researchers are doing this study to see if the addition of Glutamine to oral/tube feeding (nutrition therapy) will work better by preventing bloodstream infections, improving growth, and/or changing the make-up of bacteria in your child's intestine. Glutamine is approved by the FDA for use in adults with Short Bowel Syndrome. In this study, the investigators will be assessing how well Glutamine affects Short Bowel Syndrome in children.

NCT ID: NCT01572532 Completed - Clinical trials for Maternal Infection Affecting Newborn

Maternal Genitourinary Infections and Adverse Perinatal Outcomes

MIST
Start date: August 2010
Phase: N/A
Study type: Interventional

The primary aim of this study is to determine the impact of community-based screening and treatment of abnormal vaginal flora and urinary tract infections in early pregnancy (13-19 weeks) on preterm live birth in Sylhet district, Bangladesh. Hypothesis 1: Community-based screening and treatment of abnormal vaginal flora (Nugent score >4) and urinary tract infections in early pregnancy (13-19 weeks) will reduce the population rate of preterm live birth by at least 15%. The secondary aims of this study are: - To determine the impact of community-based screening and treatment of abnormal vaginal flora and urinary tract infections on the: - proportion of pregnancies with outcomes occurring prior to 37 weeks (late miscarriage, preterm still birth and preterm live birth); and - proportion of babies with early onset neonatal sepsis. - To determine the prevalence of abnormal vaginal flora and urinary tract infections, including asymptomatic bactiuria, among pregnant women in Sylhet district, Bangladesh. - To evaluate the accuracy of simple, low-cost, point of care diagnostic tests for detecting bacterial vaginosis and urinary tract infections by community health workers in a rural, developing country setting.

NCT ID: NCT01572233 Recruiting - Clinical trials for Hepatitis C Virus Infection, Response to Therapy of

Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection

Start date: December 2011
Phase: N/A
Study type: Interventional

This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to : 1. explore the patients' physical activity preferences and develop doable activity lists during treatment period 2. examine the changes of health-related physical fitness component over interferon treatment 3. develop the Personalized Physical Activity and Psych-Education (PPAPE) Program and test its effects on decreasing fatigue, physical and psychological distress, and improving their health-related physical fitness and quality of life in patients with chronic hepatitis C receiving Interferon with Ribavirin Combination Therapy 4. evaluate the outcome of the PPAPE program on increasing adherence to therapy, the sustained virological response (SVR) in 24 weeks after the end of treatment, and the time-consuming for education program during intervention.

NCT ID: NCT01566734 Completed - Clinical trials for Surgical Site Infections

Effect of Cefazolin and Normal Saline Irrigation on Surgical Site Infections (SSIs)

Start date: December 2010
Phase: N/A
Study type: Interventional

This study conducted to assess the effects of normal saline or cefazolin irrigation on the incidence of SSIs. Hypothesis: Normal saline or cefazolin irrigation decreases the incidence of SSIs.

NCT ID: NCT01564615 Completed - Clinical trials for Catheter-Related Infections

AgION Catheter for Preventing Catheter-Related Bloodstream Infections

Start date: July 2007
Phase: N/A
Study type: Interventional

The investigators assessed if use of AgION-impregnated umbilical catheters can decrease the occurrence of catheter-related bloodstream infections (CRBSI) in preterm infants.